Explore RLT services
Our all-encompassing service aims to simplify the RLT journey and minimise time-to-treatment for your eligible patients.
What are you looking for?
top
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Image
Image
Pluvicto®▼
Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1
Prescribing Information for Pluvicto can be found at the top of the page.
Pluvicto Summary of Product Characteristics (SmPC) can be found here
Pluvicto® is the first and only approved PSMA-targeted radioligand therapy (RLT) in the United Kingdom (UK) and is available to eligible private patients in the UK.1
Image
Here, you can access relevant information on Pluvicto and a range of engaging resources to solidify your knowledge. Click the links below to explore Pluvicto's mechanism of action, dosing and administration and key efficacy and safety profile data from the VISION Trial.2
The most common (≥20%) adverse drug reactions (ADRs) occurring at a higher incidence in patients who received Pluvicto + BSoC compared to BSoC alone include fatigue, dry mouth, nausea, anaemia, decreased appetite and constipation. The most common grade 3 to 4 ADRs (≥5%) occurring at a higher incidence in patients who received Pluvicto plus BSoC compared to BSoC alone include: anaemia (12.9%), thrombocytopenia (7.9%), lymphopenia (7.8%) and fatigue (5.9%).1
Image
177Lu, lutetium; ADR, adverse drug reaction; AR, androgen receptor; BSoC, best standard of care; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; RLI, radioligand imaging; RLT, radioligand therapy; SmPC, summary of product characteristics.
References
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) Summary of Product Characteristics.
Sartor O, et al. N Engl J Med 2021;385(12):1091–1103.
UK | November 2025 | FA-11470213-1
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.